Nicoderm CQ

nicotine patch

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Nicoderm CQ, covering 2014-02-03 to 2024-03-21. Get the full timeline:

Most recent: Clinical Trial Update: A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers [Phase 1]

See pricing